FDA Investigating CAR-Related T-cell Malignancies

The FDA is investigating reports that BCMA- and CD19-directed autologous chimeric antigen receptor T-cell immunotherapies, which are used to treat a variety of blood cancers, may be causing secondary malignancies. However, the agency and hematologists say the potential benefits of the agents, which...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer discovery 2024-01, Vol.14 (1), p.9-10
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD19 Hematologic Neoplasms - therapy Humans Immunotherapy Immunotherapy, Adoptive Receptors, Antigen, T-Cell - genetics Receptors, Chimeric Antigen T-Lymphocytes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!